We are delighted that you have decided to visit our department’s website. Our mission also includes the education and mentoring of future researchers, physicians and physician-scientists and service to the AU and greater scientific community.
The research mission is focused on inventing better diagnostics and newer targeted therapies for the benign and malignant diseases of the bladder, brain, breast, eye, gastrointestinal tract, kidney, liver, and prostate. The research areas encompass biomarkers, chemoprevention, DNA damage and repair, drug resistance, the epigenome, immunotherapy, the microbiome, molecular signaling, natural products, protein modifications and targeted therapy. Our faculties are supported by major funding agencies, and the insight gained by their work has been published in reputable peer-reviewed journals.
Home to the Biochemistry and Cancer Biology Graduate Program, the BMB Department offers PhD degrees, along with a combined MD-PhD program available to medical students. The students move on to competitive careers in academia, industry, and governmental agencies. The education mission is also served by faculty participation in undergraduate and graduate medical education, as well as the Student Educational Enrichment Program (SEEP).
Working together as a cohesive academic family, the faculty, staff, students and fellows are committed to advancing BMB’s tripartite mission.
Department of Biochemistry and Molecular Biology
Health Sciences Campus
706-721-3271
Cancer Research Center, CN-1166
706-721-6608
Augusta University student Nitish Sood took part in a third study into states' lockdowns. This time they found states that locked down late suffered up to 25% higher penetration of the disease than those who locked down earlier in the crisis.
How long will we have to shelter in place to get COVID-19 under control? According to Augusta University student Nitish Sood and his fellow researchers, the answer is months.
Aggressive colorectal cancers set up an interactive network of checkpoints to keep the immune system at bay, scientists report.
While trying to develop a comparatively easy, inexpensive way to give physicians and their patients with bladder cancer a better idea of likely outcome and best treatment options, scientists found that sophisticated new subtyping techniques designed to do this provide no better information than long-standing pathology tests.
